SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Roche and Biogen Idec, Inc. (Massachusetts) Announce Decision to Discontinue Phase 3 Ocrelizumab Clinical Development Program in Patients with Rheumatoid Arthritis